بهترین پادکست های The Uromigos (2024)

Christopher Cutie from J&J joins the show to discuss the SUNRISE bladder program with the gemcitabine-eluting pretzel across several NMIBC and MIBC states.

1
Episode 359: #UromigosLive24 - IO after IO in RCC 40:41

Play Pause

15d ago40:41

40:41

The RCC panel at Uromigos Live 2024 discusses and debates this topic.

1
Episode 358: Noticias del Dia 1 de Uromigos Live 2024 en Nashville 21:59

25d ago21:59

21:59

Eneste podcast cubrimos los temas de cáncer urotelial discutidos por los Uromigos. El impacto del estudio NIAGARA en utiliar quimio más inmunoterapia enneadyuvancia de Ca urotelial músculo invasor, el uso de pembrolizumab adyuvante después de los datos del estudio AMBASSADOR y la búsqueda de biomarcadores.…

1
Episode 357: #UromigosLive24 - Peri-operative Therapy in Bladder Cancer 1:03:10

25d ago1:03:10

1:03:10

Tom leads a panel of Shilpa Gupta, Andrea Apolo, Kala Sridhar and Petros Grivas to discuss and debate this timely topic.

1
Episode 356: #UromigosLive24 - Front-line Therapy in Papillary and Non-clear Cell RCC 26:22

26d ago26:22

26:22

Brian moderates the panel that discusses and debates TKI, vs Ipi/Nivo vs IO/TKI

1
Episode 355: #UromigosLive24 - Radioligands in prostate cancer 54:23

26d ago54:23

54:23

The Uromigos Live 2024 panel discusses recent radioligand data including PEACE-3

1
Episode 354: #UromigosLive24 - T cell directed therapy in prostate cancer 44:00

26d ago44:00

44:00

Brian hosts a panel at Uromigos Live 2024 in Nashville with Michael Morris, Tanya Dorff and Karen Autio

1
Episode 353: #UromigosLive24 ADC session 53:28

27d ago53:28

53:28

Tom moderates a live panel of Kala Sridhar, Shilpa Gupta, Andrea Apolo and Petros Grivas on the emerging ADC data in bladder cancer

1
Episode 352: ESMO 2024 - RCC and Bladder review 26:25

1M ago26:25

26:25

Tom and Brian finish discussing ESMO 2024 highlights. Even without a guest Tom still interrupts a lot.

1
Episode 351: ESMO 2024 review part 1: prostate cancer 18:48

1M ago18:48

18:48

Silke joins us to discuss ESMO 2024 highlights, then the birds start singing....

1
Episode 350: ESMO 2024 - NIAGARA 23:51

1M ago23:51

23:51

Fresh of the Presidential session address, Tom discusses his data with Petros commenting.

1
Episode 349: ESMO 2024 - Uromigos Japan!! 30:56

1M ago30:56

30:56

Uromigos Japan with Yuji, Hiroshi and Nobu is formed and discuss Hiroshi's ESMO data.

1
Episode 348: ESMO 2024 - UpFrontPSMA 33:52

1M ago33:52

33:52

Arun Azad describes this randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel vs. docetaxel in mHSPC

1
Episode 347: ESMO 2024 - DV + Pembro in Urothelial Cancer 17:59

1M ago17:59

17:59

Matt Galsky describes his ESMO 2024 abstract of disitimab vedotiin + pembrlizumab in bladder cancer

1
Episode 346: ESMO 2024 - PEACE-3: Enza/Radium-223 vs Enza in mCRPC 25:47

1M ago25:47

25:47

Silke Gillessen joins us to discuss her Presidential session from ESMO 2024

1
Episode 345: ESMO 2024 - SUNNIFORECAST: Ipi/Nivo vs SOC in Non-clear Cell RCC 31:10

1M ago31:10

31:10

Lothar Bergmann describes this investigator-initiated trial of Ipi/Nivo vs SOC in Non-clear Cell RCC

1
Episode 344: ESMO 2024 - NKT2152, a HIF inhibitor in RCC 22:32

1M ago22:32

22:32

Brad McGregor joins Brian and Tom to discuss a new HIF inhibitor, NKT2152, and preliminary data in RCC

1
Episode 343: ESMO 2024 - TiNivo-2 Trial 31:23

1M ago31:23

31:23

Katy Beckermann discusses the TiNivo-2 study presented at ESMO 2024.

1
Episode 342: ESMO 2024 Preview with Silke Gillessen 32:24

2M ago32:24

32:24

Silke joins Brian and Tom to discuss upcoming data in prostate, bladder and kidney cancer in Barcelona at ESMO 2024

1
Episode 341: Hormone Resistance in Prostate Cancer 33:05

2M ago33:05

33:05

Nima Sharifi joins Brian and Tom to discuss mechanisms of resistance to hormone therapy in prostate cancer

1
Episode 340: Cancer Immunity Cycle Update 41:50

2M ago41:50

41:50

Ira Mellman delves into the update of this classic paper and the components of an effective anti-tumor immune response.

1
Episode 339: Tres Uramigas analizan lineamientos de ESMO para GU 18:37

3M ago18:37

18:37

María, Christina y Elena analizan los cambios recientes en las directrices de la ESMO en el cáncer de riñón, vejiga y próstata.

1
Episode 338: RCC: Debulking Nephrectomy, Adjuvant Therapy Future and More 25:39

3M ago25:39

25:39

Naomi Haas joins Tom and Brian in New York City at the World GU Conference to discuss several RCC topics

1
Episode 337: Updated NCCN Guidelines in RCC 42:38

3M ago42:38

42:38

Eric Jonasch, Co-Chair of the NCCN RCC Guidelines, gives insight into the process of guideline modification and discusses updates in adjuvant, front-line and refractory RCC

1
Episode 336: Which patients are not suitable for 1st line EVP in bladder cancer 35:35

3M ago35:35

35:35

Jonathan Rosenberg and a surprise guest discuss comorbidities and treatment-related side effects.

1
Episode 335: Novel immune therapies for renal cancer 37:31

3M ago37:31

37:31

David Braun divides immune therapies into four groups and describes how novel treatments and targets work. Tom and Brian are both excited and, at times, sceptical.

1
Episodio 334 en español: Tres Uramigas ASCO 2024 36:33

4M ago36:33

36:33

Escuche nuestro primer podcast sobre los aspectos más destacados de ASCO en cáncer de vejiga, riñón y próstata

1
Episode 333: The Uromigos Cup - The Netherlands 26:20

4M ago26:20

26:20

Axel Bex, Christian Blank, Laura Mertens and Micheil Van der Heijden answer a range of relevant and sometimes irrelevant questions

1
Episode 332: The Uromigos Cup - Germany's Entry 35:55

4M ago35:55

35:55

Viktor Gruenwald, Boris Hadaschik and Gunhild Von Amsberg answer questions around GU cancer and German football

1
Episode 331: AUA 2024 NMIBC Highlights 33:56

4M ago33:56

33:56

Aditya Bagrodia describes three new drugs/studies in NMIBC.

1
Episode 330: ASCO 2024 Highlights 52:47

5M ago52:47

52:47

Silke Gillessen joins Tom and Brian, who give their opinion on the data and new 'Take Home Message' format.

1
Episode 329: Japan in the Uromigos Cup qualifying round 30:48

5M ago30:48

30:48

Nobuaki Matsubara, Hiroshi Kitamura and Yuji Miura battle through the sometimes ridiculous questions set by Tom and Brian.

1
Episode 328 ASCO24: Emergency podcast - what the NADINA trial means for preoperative GU cancer studies 26:32

5M ago26:32

26:32

David McDermott discusses the adjuvant vs neoadjuvant immune therapy trial and its wider implications.

1
Episode 327 ASCO24: CM901 and EV302 Efficacy and QOL Updates 24:02

5M ago24:02

24:02

Guru Sonpavde describes the efficacy of chemotherapy with nivolumab in lymph node only 1st line UC patients. Tom describes the QOL data for EV pembro.

1
Episode 326 ASCO24: KIM-1 in Renal Cancer 18:08

5M ago18:08

18:08

Laurence Albiges discusses this circulating biomarker which may be predictive and prognostic.

1
Episode 325 ASCO24: KN426 and the CLEAR trial - tissue based biomarkers for kidney cancer 33:44

5M ago33:44

33:44

Toni Choueiri and Brian describe similarities and differences in the biomarker findings of these two trials. Debate about the value and future of this approach breaks out.

1
Episode 324 ASCO24: SURE1 neoadjuvant sacituzumab govitecan in UC 20:43

5M ago20:43

20:43

Andrea Necchi gives us the lowdown of efficacy and toxicity of this combination.

1
Episode 323 ASCO24: TDXD in Bladder Cancer 29:47

5M ago29:47

29:47

Jonathan Rosenberg gets to grips with the data available for the bladder cohort from the TDXD Destiny pan-tumour cohort.

1
Episode 322 ASCO24: The role of ctDNA in the TheraP trial (LuPSMA vs cabazitaxel in CRPC) 22:16

5M ago22:16

22:16

Alex Wyatt describes the predictive resistance of ctDNA fraction at baseline in predicting outcome.

1
Episode 321 ASCO24: CHAARTED-2 in prostate cancer - is the sequel as good as the original? 23:25

5M ago23:25

23:25

Christos Kyriakopoulos describes the outcome of this study, where cabazitaxel with abiraterone as combined with abiraterone alone in docetaxel refractory CRPC.